CMN Weekly (20 December 2024) - Your Weekly CRISPR...
CMN Weekly
Dec. 20, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Viacyte
Main focus: Stem cell engineering for treatment of diabetes
Company stage: Clinical
Diseases: Type 1 and 2 diabetes
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: San Diego, CA, USA
Website: https://viacyte.com/
Pipeline: https://viacyte.com/pipeline/
Partners: CRISPR Therapeutics
Viacyte is developing engineered stem cells in order to treat diabetes. The company has an ongoing collaboration with CRISPR Therapeutics, for which the companies seek to develop a next generation stem cell product for all type 1 diabetes and insulin-requiring type 2 diabetes patients. The programme is currently in a research phase.
